Mechanism of action
Propofol produces its anesthetic effects primarily by acting as a positive allosteric modulator of the GABA-A receptor, the major inhibitory neurotransmitter receptor in the central nervous system. By enhancing GABA-mediated chloride conductance, propofol hyperpolarizes neurons and decreases neuronal excitability throughout the brain.
At clinically relevant concentrations, propofol potentiates GABA-A receptor activity, prolonging the opening of chloride channels and increasing inhibitory postsynaptic currents. This produces dose-dependent CNS depression ranging from mild sedation to general anesthesia. Additional mechanisms may include effects on glycine receptors and modulation of voltage-gated sodium channels, but GABA-A receptor modulation is the dominant mechanism.
Propofol has no analgesic properties. It provides only sedation and amnesia, so co-administration of analgesics is required for painful procedures. The drug also decreases cerebral metabolic rate, cerebral blood flow, and intracranial pressure, making it useful in neuroanesthesia.
- Propofol is a GABA-A receptor positive allosteric modulator with rapid onset (30–60 seconds) and quick recovery due to redistribution.
- Propofol has NO analgesic properties; always co-administer analgesics for painful procedures.
- Propofol infusion syndrome (PRIS): metabolic acidosis, rhabdomyolysis, hyperkalemia, cardiac failure; risk with high-dose prolonged infusion.
- Common side effects: hypotension (vasodilation), respiratory depression/apnea, pain on injection, bradycardia.
- Propofol is formulated as a lipid emulsion (milky white); can cause hypertriglyceridemia and supports bacterial growth.
- Propofol decreases cerebral metabolic rate, cerebral blood flow, and intracranial pressure — useful in neurosurgery.
- Green urine from phenolic metabolites is harmless and does not require intervention.
- FDA black box warning: do not use for pediatric ICU sedation due to PRIS risk.
Indications
Propofol is approved and commonly used for:
- Induction of general anesthesia in adults and children older than 3 years
- Maintenance of general anesthesia as part of balanced anesthesia or total intravenous anesthesia (TIVA)
- Procedural sedation for diagnostic and therapeutic procedures (endoscopy, cardioversion, minor surgery)
- Sedation in mechanically ventilated ICU patients for short-term use
Off-label uses
- Treatment of refractory status epilepticus
- Management of refractory nausea and vomiting (low-dose)
- Sedation for awake fiberoptic intubation (in combination with topical anesthesia)
Propofol is particularly favored when rapid emergence and early extubation are desired, such as in outpatient procedures or neurosurgical cases requiring early neurologic assessment.
Pharmacokinetics
Propofol exhibits rapid onset and offset, making it highly controllable for anesthetic purposes.
Absorption and distribution
Propofol is administered exclusively by the intravenous route as a lipid emulsion (typically 1% or 2%). It is highly lipophilic and rapidly crosses the blood-brain barrier. Onset of action is 30 to 60 seconds after IV bolus, with peak effect in 1 to 2 minutes. The drug is rapidly redistributed from the CNS to peripheral tissues, accounting for the rapid awakening after a single bolus (typically 5 to 10 minutes).
Metabolism and elimination
Propofol undergoes extensive hepatic metabolism via conjugation to glucuronide and sulfate metabolites, which are renally excreted. Extrahepatic metabolism also occurs in the lungs and kidneys. The context-sensitive half-time increases with infusion duration but remains relatively short even after prolonged infusions compared to other sedatives. The terminal elimination half-life is 4 to 7 hours. Clearance exceeds hepatic blood flow, suggesting extrahepatic metabolism is significant.
Clinical pearl: Propofol's rapid redistribution, not elimination, accounts for quick awakening after bolus dosing. With prolonged infusions, recovery depends more on elimination and can be delayed.
Adverse effects
Common adverse effects
- Pain on injection (40–70% of patients) — mitigated by prior lidocaine injection or mixing lidocaine with propofol
- Hypotension — due to peripheral vasodilation and decreased sympathetic tone; more pronounced in hypovolemic, elderly, or hemodynamically unstable patients
- Respiratory depression and apnea — dose-dependent, especially during induction
- Bradycardia — occasionally severe, especially in combination with opioids or in vagotonic patients
Serious adverse effects
Propofol infusion syndrome (PRIS) is a rare but potentially fatal complication associated with prolonged (>48 hours) high-dose (>4 mg/kg/h) propofol infusion. It is characterized by:
- Metabolic acidosis
- Rhabdomyolysis
- Hyperkalemia
- Acute kidney injury
- Cardiac arrhythmias and cardiac failure
- Hepatomegaly and lipemia
PRIS is more common in children and critically ill patients receiving catecholamine or corticosteroid infusions. Mortality is high once the syndrome develops.
Other notable effects
- Hypertriglyceridemia and pancreatitis with prolonged infusions (propofol is formulated in a lipid emulsion)
- Green discoloration of urine (phenolic metabolites; benign)
- Allergic reactions including anaphylaxis (rare; more common in patients with egg, soy, or sulfite allergy, though recent evidence suggests egg allergy is not an absolute contraindication)
- Involuntary movements, myoclonus, and opisthotonus during induction
- Bacterial contamination risk (lipid emulsion supports microbial growth; strict aseptic technique required)
Contraindications and warnings
Contraindications
- Known hypersensitivity to propofol, soy, egg, or any component of the formulation (though recent guidelines allow cautious use in egg allergy)
- Inability to provide airway management and ventilatory support
- Propofol is not approved for sedation in children undergoing procedures or in pediatric ICU patients due to increased risk of propofol infusion syndrome
Warnings and precautions
- Hemodynamic instability: use with caution in patients with compromised cardiovascular function, hypovolemia, or shock
- Respiratory depression: requires monitoring and immediate availability of airway management equipment
- Lipid load: monitor triglycerides with prolonged use; consider reduction in lipid-containing nutrition
- Propofol infusion syndrome risk: limit infusion rate and duration, especially in critically ill patients; monitor creatine kinase, lactate, and acid-base status
- Elderly patients: reduce dose due to decreased clearance and increased sensitivity
- Pregnancy category B: limited human data; use only if clearly needed
- Seizures: propofol may lower seizure threshold in epileptic patients, though it is also used to terminate status epilepticus
Drug interactions
Propofol has primarily pharmacodynamic interactions due to its CNS depressant effects.
CNS depressants
Co-administration with other CNS depressants produces additive or synergistic effects:
- Opioids (fentanyl, remifentanil, morphine) — enhanced sedation and respiratory depression; dose reduction of both agents recommended
- Benzodiazepines (midazolam, lorazepam) — additive sedative effects
- Volatile anesthetics (sevoflurane, desflurane) — reduced propofol requirement
- Alcohol and sedative-hypnotics — enhanced CNS depression
Cardiovascular drugs
- Beta-blockers and calcium channel blockers — increased risk of bradycardia and hypotension
- Vasodilators — additive hypotensive effects
Other interactions
- Neuromuscular blockers — propofol may enhance neuromuscular blockade
- Valproate, carbamazepine, and other anticonvulsants — may alter propofol metabolism, though clinical significance is unclear
- CYP enzyme interactions — propofol is metabolized primarily by conjugation, so cytochrome P450 interactions are minimal
Clinical consideration: The dose of propofol should be reduced when used in combination with other sedatives or analgesics to avoid excessive cardiorespiratory depression.
Clinical pearls
- Propofol provides sedation and amnesia but no analgesia. Always combine with analgesics for painful procedures.
- Milky white appearance: Propofol is a lipid emulsion that looks like milk; this is normal and does not indicate contamination.
- Rapid on, rapid off: Ideal for procedures requiring quick recovery and for patients needing frequent neurologic assessments.
- Context-sensitive half-time: Unlike benzodiazepines, propofol's recovery time increases only modestly with prolonged infusion duration.
- Propofol infusion syndrome (PRIS): Monitor for metabolic acidosis, rhabdomyolysis, and cardiac dysfunction in patients on high-dose or prolonged infusions. Limit infusions to <4 mg/kg/h for <48 hours when possible.
- Antiemetic properties: Low-dose propofol (10–20 mg IV) can be effective for postoperative nausea and vomiting.
- Green urine: Harmless phenolic metabolites; reassure the patient.
- Aseptic technique: Propofol supports bacterial growth; discard unused portions and use strict sterile technique. Opened vials should be used within 6 hours (or per manufacturer guidelines).
- Hypotension prophylaxis: Ensure adequate preload, consider dose reduction in elderly or hypovolemic patients, and have vasopressors readily available.
- Pain on injection: Pre-treat with 1–2 mL of 1% lidocaine or inject into a large vein with a running IV to minimize discomfort.
- Not for pediatric ICU sedation: FDA black box warning due to fatal cases of PRIS in children.
PROPOFOL — Pain on injection, Rapid onset, Oily emulsion (lipid), Pressure drop (hypotension), Only sedation (no analgesia), Fat overload (triglycerides), Ogle for PRIS (infusion syndrome), Lowers ICP.
Practice questions
1. A 52-year-old man undergoes elective colonoscopy under procedural sedation. He receives an IV bolus of propofol and fentanyl. Within 2 minutes of propofol administration, he becomes apneic and his blood pressure drops from 130/80 mmHg to 85/50 mmHg. His oxygen saturation is 88% on room air. Which of the following is the most appropriate immediate management?
2. A 9-year-old boy is admitted to the pediatric ICU with severe traumatic brain injury and is intubated and mechanically ventilated. The intensivist considers starting a propofol infusion for sedation to facilitate ventilator synchrony and reduce intracranial pressure. Which of the following is a contraindication to prolonged propofol infusion in this patient?
3. A 68-year-old woman with a history of coronary artery disease undergoes general anesthesia with propofol for a hip replacement. On postoperative day 1, the nurse reports that the patient's urine has turned green. The patient is otherwise asymptomatic with stable vital signs and normal laboratory values. Which of the following is the most appropriate next step?
Frequently asked questions
How does propofol work?
Propofol works by enhancing GABA-A receptor activity in the brain, increasing inhibitory neurotransmission and producing dose-dependent sedation and general anesthesia. It has rapid onset (30–60 seconds) and quick recovery due to redistribution. Propofol decreases cerebral metabolism, cerebral blood flow, and intracranial pressure. Importantly, it provides sedation and amnesia but has no analgesic properties, so analgesics must be given separately for pain control.
What are the side effects of propofol?
Common side effects include pain on injection, hypotension due to vasodilation, respiratory depression or apnea, and bradycardia. Serious risks include propofol infusion syndrome (PRIS), a rare but potentially fatal complication with prolonged high-dose infusion causing metabolic acidosis, rhabdomyolysis, hyperkalemia, and cardiac failure. Propofol can also cause hypertriglyceridemia, involuntary movements during induction, and green urine discoloration (benign). Allergic reactions are rare.
What is propofol infusion syndrome?
Propofol infusion syndrome (PRIS) is a rare, life-threatening complication of prolonged (>48 hours) or high-dose (>4 mg/kg/h) propofol infusion. It presents with severe metabolic acidosis, rhabdomyolysis, hyperkalemia, acute kidney injury, cardiac arrhythmias, and heart failure. PRIS is more common in critically ill patients and children. Mortality is high, and there is no specific treatment other than immediate discontinuation of propofol and supportive care. The FDA contraindicates propofol for pediatric ICU sedation due to this risk.
Is propofol a controlled substance?
Propofol is not classified as a federally controlled substance under the DEA Controlled Substances Act in the United States. However, due to potential for abuse and diversion among healthcare workers, some states have implemented their own regulations, and many hospitals treat it as a controlled drug with strict tracking and handling protocols. Propofol abuse can lead to rapid dependence and fatal respiratory depression.
Propofol vs midazolam — what is the difference?
Propofol is a rapid-onset, short-acting IV anesthetic with quick recovery due to redistribution, while midazolam is a benzodiazepine with slower onset and longer duration due to accumulation with repeat dosing. Propofol has more predictable recovery and is preferred when quick awakening is needed. Midazolam has a reversal agent (flumazenil) and causes less hypotension but longer sedation. Propofol provides deeper sedation but no analgesia; midazolam provides anxiolysis and amnesia. Propofol carries risk of propofol infusion syndrome with prolonged use, whereas midazolam accumulates and prolongs emergence.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N01AX10
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.